Live Breaking News & Updates on Substantially Increasing Its

Oncocyte Announces $25 Million Registered Offering
Offering Led by Current Shareholder and Healthcare Investor, Pura Vida Investments, Substantially Increasing Its Holdings
Further Strengthens Balance Sheet to Support Ongoing Commercial and Development Activities across Cancer Care Continuum
IRVINE, Calif., Jan. 20, 2021 Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it has entered into definitive agreements with its two largest institutional investors to purchase approximately $25 million of Oncocyte’s common shares in a registered offering priced at $3.424 per share (“at market”), which was the average of the last five closing prices. The lead investor in the offering, Pura Vida Investments, LLC, a fundamentally driven, healthcare-focused registered investment advisor, increases its ownership of Oncocyte f ....

United States , United Kingdom , Determa Mx , Ron Andrews , Pura Vida , Development Activities , Office Of Oncocyte , Company Determa , Oncocyte Corporation Form , Exchange Commission , Oncocyte Corporation , Phd Lifesci Communications , Investor Contact Bob Yedid Lifesci Advisors , Its Holdings , Pura Vida Investments , Offering Led , Current Shareholder , Healthcare Investor , Substantially Increasing Its , Strengthens Balance Sheet , Support Ongoing Commercial , Cancer Care , Broadwood Partners , Chief Executive Office , Managing Member , Contact Bob Yedid Lifesci Advisors ,